ACAD
Acadia Pharmaceuticals Inc

13,128
Mkt Cap
$4.06B
Volume
1.24M
52W High
$26.65
52W Low
$13.40
PE Ratio
15.45
ACAD Fundamentals
Price
$24.02
Prev Close
$23.64
Open
$23.29
50D MA
$22.42
Beta
0.98
Avg. Volume
1.95M
EPS (Annual)
$1.36
P/B
4.43
Rev/Employee
$1.46M
Loading...
Loading...
News
all
press releases
Los Angeles Capital Management LLC Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD
Los Angeles Capital Management LLC trimmed its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 54.1% during the second quarter, according to its most recent filing with the...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
James Daly Sells 30,000 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) Director James Daly sold 30,000 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an...
MarketBeat·2d ago
News Placeholder
ACADIA Pharmaceuticals (NASDAQ:ACAD) Director James Daly Sells 30,000 Shares
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) Director James Daly sold 30,000 shares of the firm's stock in a transaction on Monday, November 10th. The shares were sold at an average...
MarketBeat·2d ago
News Placeholder
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·3d ago
News Placeholder
Analysts Issue Forecasts for ACAD Q1 Earnings
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for ACADIA Pharmaceuticals in a report released...
MarketBeat·7d ago
News Placeholder
Leerink Partnrs Has Positive Outlook for ACAD Q4 Earnings
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at Leerink Partnrs boosted their Q4 2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors...
MarketBeat·7d ago
News Placeholder
ACADIA Pharmaceuticals (NASDAQ:ACAD) Raised to Buy at Wall Street Zen
Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·7d ago
News Placeholder
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $32.00 by Analysts at Royal Bank Of Canada
Royal Bank Of Canada cut their price target on shares of ACADIA Pharmaceuticals from $34.00 to $32.00 and set an "outperform" rating on the stock in a report on Thursday...
MarketBeat·8d ago
News Placeholder
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
Zacks·8d ago
News Placeholder
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
Zacks·8d ago

Latest ACAD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.